Use of Multiple Sclerosis Drugs Among Pregnant Women

    Basic Details
    Date Posted
    Thursday, December 6, 2018
    Status
    Complete
    Medical Product
    alemtuzumab
    daclizumab
    dalfampridine
    dimethyl fumarate
    fingolimod
    glatiramer acetate
    interferon beta-1A
    interferon beta-1A/albumin
    interferon beta-1B
    mitoxantrone
    natalizumab
    peginterferon beta-1a
    teriflunomide
    Health Outcome(s)
    pregnancy
    Description

    This report contains estimates of multiple sclerosis (MS) drug use before, during, and after pregnancies resulting in a live-born delivery, among women in the Sentinel Distributed Database (SDD). Data from January 1, 2001 to August 31, 2017 from 16 Data Partners contributing to the SDD were included in this report. This request was distributed to Data Partners on November 20, 2017.

    Additional Details
    FDA Center
    CDER
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    Pregnant women and women of reproductive age
    Data Sources
    Sentinel Distributed Database (SDD)